This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / MoonLake Immunotherapeutics Class...
Business class action

MoonLake Immunotherapeutics Class Action Lawsuit

Analysis based on 18 articles · First reported Oct 16, 2025 · Last updated Nov 01, 2025

Sentiment
-20
Attention
3
Articles
18
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Alladapt Immunotherapeutics could negatively impact its stock price due to potential financial liabilities and damage to investor confidence. For Rosen Law Firm, this action reinforces its position as a leading investor rights law firm.

Biotechnology Legal Services
Event Summary

Rosen Law Firm has filed a class action lawsuit against Alladapt Immunotherapeutics on behalf of investors who purchased common stock between March 10, 2024, and September 29, 2025. The lawsuit alleges that Alladapt Immunotherapeutics made false and misleading statements regarding the purported superiority of its drug SLK over monoclonal antibodies like BIMZELX. Specifically, the complaint claims that Alladapt Immunotherapeutics failed to disclose that SLK and BIMZELX share the same molecular targets, and that SLK's distinct Nanobody structure would not offer superior clinical benefits or translate to better clinical efficacy. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of December 15, 2025. Philip Kim and Lawrence Rosen of Rosen Law Firm are leading the efforts.

Entities Involved
priv
Alladapt Immunotherapeutics
Alladapt Immunotherapeutics is the defendant in a class action lawsuit, accused of making false and misleading statements regarding its drug SLK, which could lead to significant financial damages and reputational harm.
Importance 100.0 Sentiment -50.0
priv
Rosen Law Firm
Rosen Law Firm is actively filing and encouraging investors to join a class action lawsuit against Alladapt Immunotherapeutics, seeking compensation for alleged misleading statements.
Importance 90.0 Sentiment 50.0
per
Philip Kim
Philip Kim, an attorney at Rosen Law Firm, is listed as a contact for investors interested in joining the class action lawsuit against Alladapt Immunotherapeutics.
Importance 40.0 Sentiment 20.0
per
Lawrence Rosen
Lawrence Rosen, founding partner of Rosen Law Firm, is mentioned for his leadership in securities class actions and is a contact for the Alladapt Immunotherapeutics lawsuit.
Importance 40.0 Sentiment 20.0
Relationships
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.